Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $38.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky’s rating is based on the promising potential of Enliven Therapeutics’ lead program, ELVN-001, which is currently in Phase 1 development for treating chronic myeloid leukemia (CML). The drug has shown a 24-week major molecular response (MMR) achievement rate of 26%, which is higher than the rate observed in a similar Phase 1 trial of Scemblix. This suggests a favorable potential effect size for future studies.
Moreover, ELVN-001 has demonstrated a strong safety profile, with no significant arterial occlusive events, a common issue with other treatments. The company is also planning to expand the study to include earlier line patients, indicating confidence in the drug’s efficacy and safety. These factors, combined with the company’s strategic planning for future regulatory meetings, contribute to the Buy rating.